What Determines Regulatory Status

Two products can share the exact same active-ingredient name and still occupy completely different regulatory status — a distinction that gets lost every time a headline talks about a “generic” or “copy” of a familiar drug. Novo Nordisk’s July 2026 announcement that it will launch Extensior, an authorized copy of Ozempic, in South Africa is a useful real-world example of exactly how many categories that one ingredient name can actually span.

The Extensior Case: Same Ingredient, Different Product

Extensior uses the identical active pharmaceutical ingredient, manufacturing process, and delivery device as branded Ozempic — but it is sold under a different name, by the same manufacturer, at a lower price point, through a formal partnership with Acino/Arcera. It is being positioned specifically to compete with the unlicensed gray-market semaglutide products that have proliferated in markets with limited legal supply.

That framing matters because it draws a sharp line: Extensior is still manufactured by Novo Nordisk, under the same quality systems, with the same regulatory oversight as Ozempic itself. It is not the same thing as a compounded version prepared by a pharmacy, and it is not the same thing as an unauthorized product sold online. Same ingredient name; four very different possible categories underneath it.

Four Categories, Four Different Regulatory Realities

1. FDA-Approved Branded or Authorized-Generic Drugs

These products (branded Ozempic, Wegovy, Zepbound, Mounjaro, and authorized copies like Extensior) go through full FDA review of the finished product — not just the active ingredient, but the manufacturing process, device, stability data, and quality controls. The finished product itself carries FDA approval.

2. Traditional Pharmacy Compounding (503A/503B)

Licensed compounding pharmacies can prepare customized versions of a drug for an individual patient under a valid prescription, typically when a commercial product doesn’t meet a specific clinical need. The FDA does not review or approve the finished compounded product; oversight instead runs through state pharmacy boards and federal compounding statutes (503A or 503B), which govern the process rather than certifying each individual batch.

3. Unauthorized or Gray-Market Telehealth Products

This is the category regulators have been targeting most aggressively. The FDA issued warning letters to more than 30 telehealth companies in September 2025 and February 2026, and another 25 in June 2026, largely over claims that compounded products are equivalent to FDA-approved drugs. These products may or may not come from a licensed compounding pharmacy, and the finished product has not received FDA review — regardless of what marketing claims say.

4. Research-Use-Only (RUO) Compounds

RUO products, including the catalog Portal to Wellness sells, are intended for laboratory and research use, not for human administration, and are not reviewed or approved by the FDA as drugs for any clinical use. Where a supplier or laboratory provides a certificate of analysis, it describes identity and purity as tested — but a COA is not the same thing as FDA approval of a finished pharmaceutical product, and Portal to Wellness does not represent it as such.

Comparison at a Glance

Why This Distinction Matters More Than the Ingredient Name

Manufacturing controls, concentration accuracy, sterility assurance, and regulatory review are all things that live at the level of the finished product — not the chemical name of the active ingredient. A product can share an ingredient name with an FDA-approved drug and still have none of the manufacturing oversight that made the approved version safe and consistent. That is true whether the gap comes from an unlicensed telehealth source or from a research-use compound being misused outside its intended purpose.

For anyone evaluating a source — of any product, in any of these four categories — the questions worth asking are the same: Who manufactured this? What documentation is available? Does that documentation describe the finished product, or just the raw ingredient? Extensior’s approval process, a compounding pharmacy’s state license, and a COA are three fundamentally different kinds of paperwork, and none of them are interchangeable with the others.

Open Questions for Researchers

As Extensior rolls out and the FDA’s Pharmacy Compounding Advisory Committee continues reviewing peptide bulk-substance eligibility (meeting July 23–24, 2026), it’s worth watching whether regulatory agencies move toward clearer, standardized disclosure requirements that make a product’s actual regulatory status obvious to buyers at the point of sale — rather than leaving buyers to infer it from an ingredient name alone.

All compounds referenced in this article are available for research use only. This article is provided for informational and educational purposes. No therapeutic claims are made or implied.